abstract |
Aspects of the invention relate to compounds of Formula 1 or Formula 2 below and pharmaceutical formulations thereof and the treatment of multiple central nervous system disorders using the pharmaceutical formulations. In certain embodiments, surprisingly advantageously includes the use of various compounds that exhibit improved pharmacokinetic and therapeutic properties compared to pivagabin. |